← Back to Screener
Cytek Biosciences, Inc. Common Stock (CTKB)
Price$4.57
Favorite Metrics
Price vs S&P 500 (26W)10.99%
Price vs S&P 500 (4W)-6.59%
Market Capitalization$592.62M
All Metrics
P/CF (Annual)22.57x
Book Value / Share (Quarterly)$2.66
P/TBV (Annual)1.99x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)7.10%
Cash Flow / Share (Quarterly)$-0.07
Price vs S&P 500 (YTD)-12.85%
Gross Margin (TTM)51.84%
Net Profit Margin (TTM)-33.02%
EPS (TTM)$-0.52
10-Day Avg Trading Volume0.50M
EPS Excl Extra (TTM)$-0.52
Revenue Growth (5Y)16.77%
EPS (Annual)$-0.52
ROI (Annual)-19.09%
Gross Margin (Annual)51.84%
Net Profit Margin (5Y Avg)-7.68%
Cash / Share (Quarterly)$2.03
Revenue Growth QoQ (YoY)8.12%
ROA (Last FY)-14.42%
Revenue Growth TTM (YoY)0.52%
EBITD / Share (TTM)$-0.19
ROE (5Y Avg)-4.55%
Operating Margin (TTM)-20.04%
Cash Flow / Share (Annual)$-0.07
P/B Ratio1.73x
P/B Ratio (Quarterly)1.89x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)2.52x
Net Interest Coverage (TTM)4.47x
ROA (TTM)-13.77%
EV / EBITDA (TTM)299.17x
EPS Incl Extra (Annual)$-0.52
Current Ratio (Annual)5.04x
Quick Ratio (Quarterly)4.27x
3-Month Avg Trading Volume0.86M
52-Week Price Return25.61%
EV / Free Cash Flow (Annual)22.53x
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$2.53
P/S Ratio (Annual)2.94x
Asset Turnover (Annual)0.44x
52-Week High$6.18
Operating Margin (5Y Avg)-7.72%
EPS Excl Extra (Annual)$-0.52
CapEx CAGR (5Y)22.00%
26-Week Price Return19.74%
Quick Ratio (Annual)4.27x
13-Week Price Return-17.09%
Total Debt / Equity (Annual)0.02x
Current Ratio (Quarterly)5.04x
Enterprise Value$508.584
Revenue / Share Growth (5Y)17.33%
Asset Turnover (TTM)0.42x
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)2.10x
Pretax Margin (Annual)-14.81%
Cash / Share (Annual)$2.03
3-Month Return Std Dev39.98%
Gross Margin (5Y Avg)57.47%
Net Income / Employee (TTM)$-0
ROE (Last FY)-19.47%
Net Interest Coverage (Annual)-0.26x
EPS Basic Excl Extra (Annual)$-0.52
P/FCF (TTM)27.37x
Receivables Turnover (TTM)3.27x
Total Debt / Equity (Quarterly)0.02x
EPS Incl Extra (TTM)$-0.52
Receivables Turnover (Annual)3.27x
ROI (TTM)-17.70%
P/S Ratio (TTM)2.94x
Pretax Margin (5Y Avg)-4.08%
Revenue / Share (Annual)$1.58
Tangible BV / Share (Annual)$2.53
Price vs S&P 500 (52W)-9.48%
Year-to-Date Return-8.71%
5-Day Price Return0.44%
EPS Normalized (Annual)$-0.52
ROA (5Y Avg)-3.39%
Net Profit Margin (Annual)-33.02%
Month-to-Date Return5.49%
Cash Flow / Share (TTM)$-0.06
EBITD / Share (Annual)$-0.19
Operating Margin (Annual)-20.04%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-4.46%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.52
P/TBV (Quarterly)1.99x
P/B Ratio (Annual)1.89x
Inventory Turnover (TTM)2.10x
Pretax Margin (TTM)-14.81%
Book Value / Share (Annual)$2.66
Price vs S&P 500 (13W)-19.95%
Beta1.27x
P/FCF (Annual)27.37x
Revenue / Share (TTM)$1.57
ROE (TTM)-18.01%
52-Week Low$2.37
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
3.91
3.80
3.91
3.91
Industry Peers — Lab Analytical Instruments(22)
| Symbol | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|
CTKBCytek Biosciences, Inc. Common Stock | 2.94x | 16.77% | 51.84% | -20.04% | $4.57 |
AAgilent Technologies Inc. | 4.83x | 5.41% | 52.60% | 20.40% | $120.96 |
WATWaters Corp | 10.18x | 6.00% | 59.28% | 25.36% | $335.61 |
MTDMettler-Toledo International | 6.66x | 5.47% | 59.37% | 26.05% | $1324.66 |
ILMNIllumina Inc | 4.69x | 6.04% | 66.61% | 18.44% | $132.86 |
RVTYRevvity, Inc. | 3.64x | -5.46% | 54.77% | 12.49% | $93.03 |
BIOBio-Rad Laboratories, Inc.Class A | 3.17x | 0.29% | 52.01% | 1.59% | $303.34 |
BIO.BBio-Rad Laboratories, Inc. Class B | 3.17x | 0.29% | 52.01% | 1.59% | $277.00 |
BRKRBruker Corporation | 1.81x | 11.57% | 47.13% | 1.40% | $41.10 |
BRKRPBruker Corporation 6.375% Mandatory Convertible Preferred Stock, Series A | 1.81x | 11.57% | 47.13% | 1.40% | $320.13 |
AVTRAvantor, Inc. | 0.88x | 0.49% | 32.65% | -3.83% | $8.50 |
About
Cytek Biosciences develops full-spectrum flow cytometry systems that enable high-resolution, sensitive cell analysis at a lower cost than conventional technologies. Its Aurora and Northern Lights platforms leverage advanced fluorescence detection to deliver superior analytical power and flexibility for research and diagnostics applications. The company generates the majority of its revenue from the United States.